Development and evaluation of a physiologically based pharmacokinetic model to predict carvedilol-paroxetine metabolic drug–drug interaction in healthy adults and its extrapolation to virtual chronic heart failure patients for dose optimization

References

• Varma MV, Pang KS, Isoherranen N, et al. Dealing with the complex drug-drug interactions: towards mechanistic models. Biopharm Drug Dispos. 2015 Mar;36(2):71–92.
   PubMed Web of Science ®Google Scholar
• Perdaems N, Blasco H, Vinson C, et al. Predictions of metabolic drug-drug interactions using physiologically based modelling: two cytochrome P450 3A4 substrates coadministered with ketoconazole or verapamil. Clin Pharmacokinet. 2010 Apr;49(4):239–258.
   PubMed Web of Science ®Google Scholar
• Gnjidic D, Johnell K. Clinical implications from drug–drug and drug–disease interactions in older people. Clin Exp Pharmacol Physiol. 2013;40(5):320–325.
   PubMed Web of Science ®Google Scholar
• Rowland M, Lesko LJ, Physiologically Based R-HA. Pharmacokinetics is impacting drug development and regulatory decision making. CPT Pharmacometrics Syst Pharmacol. 2015;4(6):313–315.
   PubMedGoogle Scholar
• McTavish D, Campoli-Richards D, Sorkin EM. Carvedilol [journal article]. Drugs. 2012;45(2):232–258.
   Google Scholar
• Himmelmann LHA. Carvedilol in the treatment of hypertension - a review of the clinical data base. Scan Cardiovasc J. 1998;32(47):67–80. 1998/01/01.
   Google Scholar
• Parker BM, Rogers SL, Lymperopoulos A. Clinical pharmacogenomics of carvedilol: the stereo-selective metabolism angle. Pharmacogenomics. 2018;19(14):1089–1093.
   PubMed Web of Science ®Google Scholar
• Neugebauer G, Akpan W, Kaufmann B, et al. Stereoselective disposition of carvedilol in man after intravenous and oral administration of the racemic compound. Eur J Clin Pharmacol. 1990;38(2):S108–S111. 1990/03/01.
   PubMedGoogle Scholar
• Yoshikawa T, Port J, Asano K, et al. Cardiac adrenergic receptor effects of carvedilol. Eur Heart J. 1996;17(suppl_B):8–16.
   PubMedGoogle Scholar
• Oldham HG, Clarke SE. In vitro identification of the human cytochrome P450 enzymes involved in the metabolism of R(+)- and S(-)-carvedilol. Drug Metab Dispos. 1997 Aug;25(8):970–977.
   PubMed Web of Science ®Google Scholar
• Ohno A, Saito Y, Hanioka N, et al. Involvement of human hepatic UGT1A1, UGT2B4, and UGT2B7 in the glucuronidation of carvedilol. Drug Metab Dispos. 2004 Feb;32(2):235–239.
   PubMed Web of Science ®Google Scholar
• Takekuma Y, Yagisawa K, Sugawara M. Mutual inhibition between carvedilol enantiomers during racemate glucuronidation mediated by human liver and intestinal microsomes. Biol Pharm Bull. 2012;35(2):151–163.
   PubMed Web of Science ®Google Scholar
• Sehrt D, Meineke I, Tzvetkov M, et al. Carvedilol pharmacokinetics and pharmacodynamics in relation to CYP2D6 and ADRB pharmacogenetics. Pharmacogenomics. 2011 Jun;12(6):783–795.
   PubMed Web of Science ®Google Scholar
• Bourin M, Chue P, Guillon Y. Paroxetine: a Review. CNS Drug Rev. 2001;7(1):25–47.
   PubMedGoogle Scholar
• Sindrup SH, Brosen K, Gram LF, et al. The relationship between paroxetine and the sparteine oxidation polymorphism. Clin Pharmacol Ther. 1992 Mar;51(3):278–287.
   PubMed Web of Science ®Google Scholar
• Stout SM, Nielsen J, Welage LS, et al. Influence of metoprolol dosage release formulation on the pharmacokinetic drug interaction with paroxetine. J Clin Pharmacol. 2011 Mar;51(3):389–396.
   PubMed Web of Science ®Google Scholar
• Spina E, Scordo MG, D’Arrigo C. Metabolic drug interactions with new psychotropic agents. Fundam Clin Pharmacol. 2003;17(5):517–538.
   PubMed Web of Science ®Google Scholar
• Wessler JD, Grip LT, Mendell J, et al. The P-glycoprotein transport system and cardiovascular drugs. J Am Coll Cardiol. 2013 Jun 25;61(25):2495–2502.
   PubMed Web of Science ®Google Scholar
• Lymperopoulos A, McCrink KA, Brill A. Impact of CYP2D6 genetic variation on the response of the cardiovascular patient to carvedilol and metoprolol. Curr Drug Metab. 2015;17(1):30–36.
   PubMed Web of Science ®Google Scholar
• Weiss J, Dormann S-MG, Martin-Facklam M, et al. Inhibition of P-glycoprotein by newer antidepressants. J Pharmacol Exp Ther. 2003 Apr;305(1):197–204.
   PubMed Web of Science ®Google Scholar
• Rasool MF, Khalil F, Laer S. Predicting stereo-selective disposition of carvedilol in adult and pediatric chronic heart failure patients by incorporating pathophysiological changes in organ blood flows - A physiologically based pharmacokinetic approach. Drug Metab Dispos. 2016;44(7):1103–1115.
   PubMed Web of Science ®Google Scholar
• Stout SM, Nielsen J, Bleske BE, et al. The impact of paroxetine coadministration on stereospecific carvedilol pharmacokinetics. J Cardiovasc Pharmacol Ther. 2010 Dec;15(4):373–379.
   PubMed Web of Science ®Google Scholar
• Jamei M, Turner D, Yang J, et al. Population-based mechanistic prediction of oral drug absorption. Aaps J. 2009 Jun;11(2):225–237.
   PubMed Web of Science ®Google Scholar
• Berezhkovskiy LM. Volume of distribution at steady state for a linear pharmacokinetic system with peripheral elimination. J Pharm Sci. 2004 Jun;93(6):1628–1640.
   PubMed Web of Science ®Google Scholar
• Wilkinson GR, Shand DG. Commentary: a physiological approach to hepatic drug clearance. Clin Pharmacol Ther. 1975 Oct;18(4):377–390.
   PubMed Web of Science ®Google Scholar
• Leithe ME, Margorien RD, Hermiller JB, et al. Relationship between central hemodynamics and regional blood flow in normal subjects and in patients with congestive heart failure. Circulation. 1984 Jan;69(1):57–64.
   PubMed Web of Science ®Google Scholar
• Lee R, Beard J, Aldoori M. Blood flow to the limbs. In: Salmasi A-M, Iskandrian A, editors. Cardiac output and regional flow in health and disease. developments in cardiovascular medicine. Vol. 138. Springer Netherlands; 1993. p. 505–522.
   Google Scholar
• Mikami A, Ohtani H, Hori S, et al. Pharmacokinetic model incorporating mechanism-based inactivation of CYP2D6 can explain both non-linear kinetics and drug interactions of paroxetine. Int J Clin Pharmacol Ther. 2013 May;51(5):374–382.
   PubMed Web of Science ®Google Scholar
• Graff DW, Williamson KM, Pieper JA, et al. Effect of fluoxetine on carvedilol pharmacokinetics, CYP2D6 activity, and autonomic balance in heart failure patients. J Clin Pharmacol. 2001 Jan;41(1):97–106.
   PubMed Web of Science ®Google Scholar
• Tenero D, Boike S, Boyle D, et al. Steady-state pharmacokinetics of carvedilol and its enantiomers in patients with congestive heart failure. J Clin Pharmacol. 2000 Aug;40(8):844–853.
   PubMed Web of Science ®Google Scholar
• Kaijser M, Johnsson C, Zezina L, et al. Elevation of cyclosporin A blood levels during carvedilol treatment in renal transplant patients. Clin Transplant. 1997 Dec;11(6):577–581.
   PubMed Web of Science ®Google Scholar
• Giessmann T, Modess C, Hecker U, et al. CYP2D6 genotype and induction of intestinal drug transporters by rifampin predict presystemic clearance of carvedilol in healthy subjects. Clin Pharmacol Ther. 2004 Mar;75(3):213–222.
   PubMed Web of Science ®Google Scholar
• Aiba T, Ishida K, Yoshinaga M, et al. Pharmacokinetic characterization of transcellular transport and drug interaction of digoxin in Caco-2 cell monolayers. Biol Pharm Bull. 2005 Jan;28(1):114–119.
   PubMed Web of Science ®Google Scholar